Free shipping on all orders over $ 500

APTO-253

Cat. No. M13539

All AbMole products are for research use only, cannot be used for human consumption.

APTO-253 Structure
Synonym:

LOR-253; LT-253

Size Price Availability Quantity
10mM*500uL in DMSO USD 55 In stock
1mg USD 36 In stock
2mg USD 50 In stock
5mg USD 72 In stock
10mg USD 110 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor. APTO-253 has antiarthritic activity. APTO-253 (LOR-253) is an inducer of KLF4. APTO-253 (5 μM) induces KLF4 expression, and enhances apoptosis induced by NSC 119875 in both SKOV3 and OVCAR3 cells. APTO-253 (5 μM) also leads to G1 phase arrest and reduces S and G2/M phase cells in SKOV3 and OVCAR3 cells.

APTO-253 (LOR-253; 15 mg/kg; IV; twice per day for 2 consecutive days per week for 14 days) has antiarthritic activity in a CIA model.

Chemical Information
Molecular Weight 367.38
CAS Number 916151-99-0
Solubility (25°C) DMSO 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Wataru Nakajima, et al. Genes (Basel). Krüppel-Like Factor 4 and Its Activator APTO-253 Induce NOXA-Mediated, p53-Independent Apoptosis in Triple-Negative Breast Cancer Cells

[2] Michael J Duffy, et al. Cancer Treat Rev. MYC as a target for cancer treatment

[3] Saikat Pal, et al. Phys Chem Chem Phys. An in silico investigation of the binding modes and pathway of APTO-253 on c-KIT G-quadruplex DNA

[4] Andrea Local, et al. Mol Cancer Ther. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells

[5] Cheng-Yu Tsai, et al. Mol Cancer Ther. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency

Related c-Myc Products
10058-F4

10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression.

10074-G5

10074-G5 is a c-Myc/Max interaction inhibitor, which binds to a different specific binding site (region) of C-Myc than 10054-F4.

ML327

ML327 is a blocker of MYC, which mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.

MYCi975

MYCi975 (Nuc-0200975) is an orally active MYC inhibitor that disrupts MYC/MAX interactions, promotes MYC T58 phosphorylation and MYC degradation, and impairs myC-driven gene expression. MYCi975 (NUC-0200975) has strong anti-tumor effect and good tolerance, increasing tumor immune cell infiltration and enhancing tumor sensitivity against PD1 immune studies.

IZCZ-3

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: APTO-253, LOR-253; LT-253 supplier, c-Myc, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.